Biotech Stocks To Follow Now - April 29th

SpringWorks Therapeutics, AbbVie, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Shares of NASDAQ SWTX traded up $0.04 during mid-day trading on Tuesday, hitting $46.22. 9,379,443 shares of the company's stock traded hands, compared to its average volume of 1,813,957. The company has a market capitalization of $3.47 billion, a P/E ratio of -13.28 and a beta of 0.79. The company's 50-day moving average is $46.01 and its two-hundred day moving average is $40.74. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00.

Read Our Latest Research Report on SWTX

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE ABBV traded up $2.65 during midday trading on Tuesday, hitting $194.99. The company's stock had a trading volume of 2,197,572 shares, compared to its average volume of 6,048,418. The business's 50 day moving average is $196.75 and its two-hundred day moving average is $187.12. The firm has a market cap of $344.94 billion, a P/E ratio of 81.21, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. AbbVie has a 12-month low of $153.58 and a 12-month high of $218.66.

Read Our Latest Research Report on ABBV

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of Thermo Fisher Scientific stock traded up $5.31 during trading on Tuesday, hitting $426.65. 891,888 shares of the stock traded hands, compared to its average volume of 1,743,802. The stock's fifty day simple moving average is $485.08 and its 200 day simple moving average is $525.48. Thermo Fisher Scientific has a 52-week low of $409.85 and a 52-week high of $627.88. The firm has a market cap of $161.06 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Read Our Latest Research Report on TMO

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.